Investor interest in the urology space waxes and wanes; it's attractive because as a niche specialty it has some pretty big patient populations. Benign prostatic hyperplasia (BPH), the benign enlargement of the prostate over time, affects 90% of men by the time they're 80, and half of men at age 60. In Europe, according to European Markets for Benign Prostatic Hyperplasia Drugs, Devices, and Therapies, a report recently published by FDC-Windhover Information's Medtech Insight division, that's 28 million men. But urology goes out of favor from time to time because so many drugs and device therapies that initially looked promising failed to address the majority of BPH sufferers, or worse, caused side effects in a very sensitive part of the body. Now, we seem to be heading into an up-cycle for BPH, in both the device and pharmaceutical segments.